The FDA cleared reSET in September 2017, making it the first authorized app to aid in the treatment of alcohol, cocaine and stimulant substance use disorders. The prescription-only app delivers 12 weeks of interactive cognitive behavioral therapy to patients enrolled in outpatient treatment, in an effort to increase skills retention.
The app also encourages patients to report information on substance use, cravings and triggers, which reSET presents to clinicians through a data dashboard.
“This is an example of how innovative digital technologies can help provide patients access to additional tools during their treatment,” Carlos Peña, PhD, director of the division of neurological and physical medicine devices in the FDA’s Center for Devices and Radiological Health, said after the agency cleared the app in 2017.
“More therapy tools means a greater potential to help improve outcomes, including abstinence, for patients with substance use disorder,” he continued.
More articles on supply chain:
Many pharma apps won’t be regulated under proposed FDA framework
Emergency Ebola test, new COPD treatment & more: 4 latest FDA approvals
FDA’s cybersecurity policies for postmarket medical devices are ‘insufficient,’ OIG finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
